Growth Hormone Treatment in Children — Cost, Top Hospitals & Success Rates | MyMedicPlus

Growth hormone (GH) therapy involves the administration of recombinant human growth hormone (rhGH) — a biosynthetic analogue of the naturally occurring pituitary growth hormone (somatotropin) — to children with conditions causing poor linear growth. Growth hormone is a 191-amino-acid protein normally secreted by the anterior pituitary gland, primarily during sleep, in response to growth hormone-releasing hormone (GHRH) from the hypothalamus. GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates most of the growth-promoting effects at the epiphyseal growth plates, skeletal muscle, and adipose tissue. Recombinant GH (e.g., Genotropin, Humatrope, Norditropin, Nutropin, Saizen, Omnitrope) became available in 1985 after the withdrawal of pituitary-derived cadaveric GH (associated with Creutzfeldt-Jakob disease). Treatment is administered by subcutaneous injection 6–7 nights per week, typically at bedtime to mimic the natural nocturnal GH pulse, using a pre-filled pen injection device. A once-weekly long-acting GH preparation (somatrogon — Ngenla; lonapegsomatropin — Skytrofa) is now available and approved for GH deficiency, offering a significant quality-of-life advantage for children and families by reducing injection frequency from 7 to 1 per week. Treatment duration spans years — from diagnosis to near-adult height, typically when the epiphyses close (bone age 14–16 in girls, 16–18 in boys).

FDA and EMA-approved indications for rhGH in children include: growth hormone deficiency (GHD) — isolated GHD (congenital pituitary malformation, perinatal hypoxia, craniopharyngioma) or multiple pituitary hormone deficiency (MPHD) from tumours, radiation, or trauma; Turner syndrome — chromosomal disorder (45,X or mosaic) in girls causing short stature; Prader-Willi syndrome — genomic imprinting disorder causing hypotonia, hyperphagia, and short stature; SGA (small for gestational age) children who fail to show catch-up growth by age 2–4 years; chronic kidney disease (CKD) causing poor growth; SHOX gene deficiency — haploinsufficiency of the short stature homeobox gene causing Leri-Weill dyschondrosteosis; idiopathic short stature (ISS) — children in the lowest 1.2% of height for age/sex without identifiable cause (approved in USA but not universally endorsed). GH therapy is also used off-label for Noonan syndrome, Silver-Russell syndrome, skeletal dysplasias, and some inflammatory bowel disease cases. In adults, GHD following childhood onset or acquired in adulthood (from pituitary tumour, radiation, or trauma) is an approved indication for continued or initiated GH therapy.

Children being considered for rhGH therapy require comprehensive endocrine evaluation at a specialist paediatric endocrinology centre. Diagnostic workup includes: detailed growth history with growth velocity calculation (normal is 5–7 cm/year in prepubertal school-age children); accurate height measurement with stadiometer; midparental height calculation; bone age (left hand X-ray) to assess growth potential and skeletal maturity; IGF-1 and IGFBP-3 levels (low in GHD, variably low in other conditions); GH stimulation tests (clonidine, glucagon, insulin tolerance test — peak GH below 10 ng/mL on 2 tests confirms GHD); MRI of the hypothalamic-pituitary axis (to identify structural causes); and assessment of other pituitary hormones (TSH/T4, ACTH/cortisol, LH/FSH/sex steroids, prolactin, vasopressin/ADH). Girls with unexplained short stature require karyotype to exclude Turner syndrome. Children with active malignancy are generally not eligible for rhGH. Children must have open epiphyseal growth plates (confirmed on bone age X-ray) to benefit. Optimal response requires early initiation before pubertal bone age advancement.

GH therapy produces significant and sustained increases in height velocity and final adult height in all approved indications. In GH-deficient children, treatment increases height velocity from a pre-treatment mean of 3–4 cm/year to 9–12 cm/year in the first year (catch-up growth) and 6–8 cm/year thereafter. Randomised controlled data demonstrate a mean increase in final adult height of 10–12 cm compared to untreated GHD children. In Turner syndrome, GH therapy increases final adult height by 7–8 cm versus untreated patients; early initiation before age 8–9 produces the greatest gain. In SGA children, treatment increases final adult height by 7–8 cm and achieves normal adult height range in the majority when started before age 4. Beyond height, GH has important metabolic benefits: reduction of body fat, increase in lean muscle mass, improvement in bone mineral density, and favourable cardiovascular risk profile. In GHD adults, GH therapy improves body composition, bone density, lipid profile, exercise capacity, and quality of life. Once-weekly GH preparations (somatrogon, lonapegsomatropin) achieve equivalent efficacy to daily injections with substantially improved adherence and quality of life.

Recombinant GH is generally well-tolerated in children. Common side effects include: injection site reactions (redness, bruising, lipohypertrophy — minimised by site rotation); fluid retention and oedema (particularly at treatment initiation — transient); benign intracranial hypertension (pseudotumour cerebri) — rare (0.2–1%), presenting with headache, visual disturbance, and papilloedema; slipped capital femoral epiphysis (SCFE) — increased risk during rapid growth; scoliosis progression in predisposed individuals; and gynaecomastia (rare). Glucose metabolism: GH therapy mildly impairs insulin sensitivity — fasting glucose and HbA1c should be monitored annually, particularly in at-risk patients (Prader-Willi, obesity, family history of T2DM). Cancer risk: GH does not increase the risk of de novo malignancy in children without prior cancer history at therapeutic doses. In children with a history of malignancy, GH can generally be restarted after a 1–2 year cancer-free period after careful risk-benefit discussion. Creutzfeldt-Jakob disease risk was associated with cadaveric GH (used before 1985) — recombinant GH carries no prion risk. Idiopathic GH treatment (ISS) has the weakest benefit-risk ratio and requires particularly careful informed consent.

Growth hormone therapy is expensive globally due to the complex manufacturing process of recombinant protein biologics. In India, daily GH injections cost USD 150–400 per month depending on the brand and dose (Genotropin, Humatrope, Norditropin are available; Indian biosimilars such as Sero-Reco by Serum Institute or GH-Vax cost approximately 30–50% less than originator brands). Annual treatment costs range USD 1,800–5,000 in India versus USD 15,000–50,000 per year in the USA (originator brands) and GBP 8,000–20,000 in the UK (where NICE restricts GH to GHD and Turner syndrome). Once-weekly somatrogon (Ngenla) is available in India at approximately USD 200–350 per injection (monthly cost slightly higher than daily GH but with quality-of-life benefit). Paediatric endocrinology follow-up in India (quarterly growth monitoring, IGF-1 measurement, bone age X-rays) costs USD 30–80 per visit. International families travelling to India for GH initiation and monitoring benefit from India's experienced paediatric endocrinologists, biosimilar availability, and comprehensive paediatric growth disorder assessment at major centres (AIIMS, CMC Vellore, Apollo, Narayana).

Recombinant human growth hormone (rhGH) therapy is the primary treatment for confirmed GH deficiency and several other approved indications in children:

• Recombinant human GH (somatropin) — subcutaneous injection: Daily subcutaneous injection of biosynthetic recombinant human GH at doses of 25–35 micrograms/kg/day for GHD; up to 45–50 micrograms/kg/day for Turner syndrome and SGA. Injections are administered nightly (when endogenous GH pulses are highest, mimicking physiological secretion) using auto-injector pen devices (Norditropin FlexPro, Genotropin GoQuick, Humatrope). Most children and families learn self-injection within days; rotation of injection sites (abdomen, thigh, buttock) prevents lipodystrophy.
• Weekly long-acting somatropin (Somatrogon, Ngenla): Once-weekly subcutaneous injection approved by EMA (2021) and FDA (2023) for paediatric GHD. Equivalent efficacy to daily rhGH for height velocity and IGF-1 normalisation, with dramatically improved adherence — daily injection burden is the main cause of GH therapy non-adherence. Increasingly preferred for adolescents and older children who are adherence-challenged.
• GnRH analogues for pubertal delay (as adjunct): In children with GHD approaching puberty before reaching acceptable height, GnRH agonists (leuprolide, triptorelin) can temporarily suppress puberty, extending the pre-pubertal growth window and allowing additional rhGH therapy before epiphyseal fusion. Used selectively in combination with rhGH.
• Treatment of underlying cause: Where GHD results from a craniopharyngioma, GH-producing region tumour, or pituitary adenoma, surgical resection ± radiotherapy addresses the tumour before or alongside rhGH replacement. Other pituitary hormone deficiencies (thyroid, adrenal, antidiuretic hormone) must be treated concurrently.

Growth hormone therapy requires regular structured monitoring for efficacy, safety, and dosing:

• Every 3–6 months: Height and weight measurement — plotted on growth charts to assess height velocity response. Target: height velocity >2 cm/year above pre-treatment baseline; children not responding should have adherence reviewed and diagnosis re-evaluated. IGF-1 measurement — adjusted to upper half of age- and sex-specific normal range; over-treatment (IGF-1 >+2 SD) requires dose reduction.
• Annual review: Bone age X-ray (left hand and wrist) — bone age advancement allows prediction of final adult height. Pituitary MRI if GHD due to intracranial pathology. Fasting glucose and insulin — rhGH mildly increases insulin resistance; monitor for impaired fasting glucose, particularly in obese patients and Turner syndrome. Thyroid function — secondary hypothyroidism may develop or be unmasked during GH therapy.
• Injection site review: Lipodystrophy (lipoatrophy or lipohypertrophy) at injection sites is common with fixed-site injection — rotate sites systematically. Inspect at every visit.
• Transition to adult care: GH treatment is typically discontinued when height velocity falls below 2 cm/year after bone age is 14–15 years (girls) or 16–17 years (boys) indicating near-complete epiphyseal fusion. Adults with confirmed persistent GHD (childhood-onset GHD) should be retested at 18 years and offered adult GH replacement if confirmed.

Recombinant GH is the evidence-based treatment for GHD and approved indications. Alternatives are limited:

• Mecasermin (IGF-1 — Increlex): Recombinant human IGF-1 for children with severe primary IGF-1 deficiency (GH receptor deficiency, GH gene deletions with anti-GH antibodies). Not suitable for standard GHD where GH axis is functional.
• Somatrogon (weekly GH): For confirmed GHD, provides equivalent height gains to daily somatropin with once-weekly dosing — a major practical alternative for adherence-challenged patients.
• Addressing modifiable causes of growth failure: Optimising nutrition (catch-up growth in undernutrition), treating coeliac disease or Crohn's disease, managing hypothyroidism, optimising asthma and corticosteroid use — all can produce significant catch-up growth without GH therapy. These should be excluded before GHD diagnosis.
• No treatment (watchful waiting): Appropriate for children with familial short stature and normal GH status (variant of normal, not a disease). Psychological support and realistic height expectation counselling are important; GH therapy is not indicated and not effective in the absence of GHD or another approved indication.